Table III.
Clinicopathologic characteristics of patients with hepatocellular carcinoma (n=114).
| Characteristics | Value |
|---|---|
| Sex, n | |
| Male | 84 |
| Female | 30 |
| Mean age ± std, years | 66.5±12.6 |
| Age, n | |
| >65 years | 54 |
| ≤65 years | 60 |
| Etiology, n | |
| Hepatitis B | 97 |
| Hepatitis C | 17 |
| Child-Pugh classification, n | |
| A | 89 |
| B | 20 |
| C | 5 |
| Liver cirrhosis, n | |
| Present | 100 |
| Absent | 14 |
| Tumor size, n | |
| ≤5 cm | 59 |
| >5 cm | 55 |
| Tumor number, n | |
| Single | 80 |
| Multiple | 34 |
| Median maximum diameter of multiple tumors, cm (range) | 3.4 (0.8–7.5) |
| Maximum diameter of multiple tumors, n | |
| <2 cm | 12 |
| 2–5 cm | 12 |
| >5 cm | 10 |
| Number of multiple tumors, n | |
| 2 | 20 |
| 3 | 8 |
| 4 | 3 |
| 5 | 2 |
| >5 | 1 |
| AFP before TACE treatment, n (ng/ml) | |
| <200 | 54 |
| ≥200 | 60 |
| AFP after TACE treatment, n (ng/ml) | |
| <200 | 99 |
| ≥200 | 15 |
| TACE response, n | |
| Poor | 55 |
| Well | 59 |
| Median follow-up, months (range) | 23.5 (3–82) |
| Overall mortality | 37 (32.5%) |
AFP, α-fetoprotein; TACE, transarterial chemoembolization.